In concordance, ADH-1, which is an N-cadherin antagonist peptide with FDA approval for the treatment of solid tumors, has been shown to both inhibit the malignant behavior of ALL cells and increase leukemia cell death by apoptosis [116]. The gene discussed is ADH1A; the disease is leukemia.